New drug targets 'Undruggable' cancer mutation in lung and colon tumors
NCT ID NCT04699188
Summary
This study is testing a new drug called JDQ443, both alone and in combination with other treatments, for patients with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to find safe doses and see if the treatments can shrink tumors. It is for adults with cancers like non-small cell lung cancer or colorectal cancer who have already tried standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University School of Medicine-Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Melbourne, Victoria, 3000, Australia
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Montreal, Quebec, H2W 1T8, Canada
-
Novartis Investigative Site
Guangzhou, Guangdong, 510080, China
-
Novartis Investigative Site
Beijing, 100036, China
-
Novartis Investigative Site
Copenhagen, DK-2100, Denmark
-
Novartis Investigative Site
Lyon, 69373, France
-
Novartis Investigative Site
Marseille, 13273, France
-
Novartis Investigative Site
Villejuif, 94800, France
-
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
Dresden, Saxony, 01307, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Hong Kong, 999077, Hong Kong
-
Novartis Investigative Site
Brescia, BS, 25123, Italy
-
Novartis Investigative Site
Milan, MI, 20133, Italy
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Nagoya, Aichi-ken, 4668560, Japan
-
Novartis Investigative Site
Kashiwa, Chiba, 2778577, Japan
-
Novartis Investigative Site
Osaka, Osaka, 5418567, Japan
-
Novartis Investigative Site
Chuo Ku, Tokyo, 1040045, Japan
-
Novartis Investigative Site
Koto Ku, Tokyo, 1358550, Japan
-
Novartis Investigative Site
Amsterdam, 1066 CX, Netherlands
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Seoul, 03722, South Korea
-
Novartis Investigative Site
Santiago Compostela, A Coruna, 15706, Spain
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Madrid, 28050, Spain
-
Novartis Investigative Site
Málaga, 29010, Spain
-
Novartis Investigative Site
Valencia, 46010, Spain
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.